Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Despite Ocrelizumab Infection Risk, Roche Sees Multiple Sclerosis Opportunity

This article was originally published in The Pink Sheet Daily

Executive Summary

Anti-CD20 molecule's future in RA was dashed by high infection risk, but Roche says the safety profile of ocrelizumab could be better in MS patients.

You may also be interested in...



Ocrevus Launching Quickly Even After Manufacturing Worries Delayed US Approval

Genentech’s ocrelizumab, a CD20-directed antibody, becomes first US-approved treatment for primary progressive multiple sclerosis and is also indicated for relapsing disease. Labeling includes warnings about infusion reactions, infections and malignancy but lacks a boxed warning or REMS.

Roche’s Ocrelizumab Poised To Seize Primary Progressive MS Opportunity

Roche plans to file the selective CD20 antibody in 2016 after releasing positive Phase III data at ECTRIMS in both relapsing-remitting and primary progressive multiple sclerosis, a debilitating form of the disease for which there are no approved drugs.

Ocrelizumab May Represent Roche’s Rebound In Neuroscience

Roche plans to file I.V. anti-CD20 antibody ocrelizumab in multiple sclerosis early in 2016, after disclosing that the drug met endpoints in two Phase III studies against Merck Serono’s Rebif.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS070394

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel